WEKO3
インデックスリンク
アイテム
Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
https://gifu-pu.repo.nii.ac.jp/records/14838
https://gifu-pu.repo.nii.ac.jp/records/14838cb89decf-9ad8-45b1-a665-4c519ca29134
Item type | 研究室原著論文(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2023-03-17 | |||||
タイトル | ||||||
タイトル | Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy. | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Antiemetics | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Antineoplastic Agents | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Cisplatin | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Dexamethasone | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Female | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Humans | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Nausea | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Retrospective Studies | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Risk Factors | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Uterine Cervical Neoplasms | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Vomiting | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
抄録 | ||||||
値 | Background/aim: Nausea and vomiting are two of the most distressing adverse events of cancer radiotherapy. The aim of this study was to examine the control rate and risk factors associated with nausea and vomiting in patients with cervical cancer receiving radiotherapy. Patients and methods: This retrospective study examined patients with cervical cancer who received radiotherapy alone or with concomitant cisplatin. Patients who received radiotherapy alone were not administered antiemetic premedication, while patients who received radiotherapy with concomitant weekly cisplatin (40 mg/m2) were administered antiemetic therapy comprising granisetron and dexamethasone. Risk factors for non-complete response (CR) were identified using multivariate logistic regression analysis. Results: Multivariate analysis indicated that younger age and concomitant weekly cisplatin were significant factors associated with non-CR across 5 weeks of treatment in patients who received radiotherapy. The proportion achieving CR among younger patients (<65 years) who received radiotherapy alone or with concomitant cisplatin was significantly lower than that among older patients (≥65 years) (Concomitant cisplatin: 27% vs. 67%, p=0.049; Radiotherapy alone: 62% vs. 91%, p=0.166). However, the proportion of patients achieving CR across 5 weeks of treatment was insufficient in all groups except for those aged ≥ 65 years who received radiotherapy alone. Conclusion: Antiemetic prophylaxis should be considered for younger patients with cervical cancer undergoing radiotherapy alone. Further, neurokinin-1 receptor antagonist should be added to 5-hydroxytryptamine type-3 receptor antagonist and dexamethasone as antiemetic prophylactic therapy for patients with cervical cancer undergoing radiotherapy with concomitant weekly doses of 40 mg/m2 cisplatin. |
|||||
書誌情報 |
en : Anticancer research 巻 42, 号 6, p. 3117-3123, 発行日 2022-06 |
|||||
DOI | ||||||
値 | 10.21873/anticanres.15800 |